Скачать или смотреть Comparing CSF biomarker & blood-based assays in brain tumor monitoring

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, comments on the challenges and opportunities in using plasma and cerebrospinal fluid (CSF) as liquid biopsy sources for brain tumor biomarkers. The blood-brain barrier limits the detection of brain tumor biomarkers in plasma, resulting in lower sensitivity, and that CSF bypasses this issue but has its own limitations. As technologies develop and more experience is gained, the dynamics between plasma and CSF will become clearer, and both can be used complementarily to monitor disease progression. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.